首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal TICAM2 Antibody

  • 中文名: TICAM2抗体
  • 别    名: TIRP; TRAM; TIRAP3; MyD88-4; TICAM-2
货号: IPDX01464
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/100-1/300 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/1000-1/2000 Human,Mouse,Rat

产品详情

参考文献

以下是3篇关于TICAM2抗体的示例参考文献(注:以下内容为模拟示例,具体文献需根据实际数据库查询):

---

1. **标题**: *"TICAM2/TRAM is required for TLR4 endosomal signaling to regulate IRF3-mediated antiviral responses"*

**作者**: Yamamoto M, et al.

**摘要**: 研究通过TICAM2抗体敲低实验,证实TICAM2在TLR4内体信号转导中的关键作用,揭示其通过激活IRF3调控抗病毒免疫反应的机制。

2. **标题**: *"Differential expression of TICAM2 in tumor-associated macrophages promotes cancer progression"*

**作者**: Li J, et al.

**摘要**: 利用TICAM2特异性抗体进行免疫组化分析,发现TICAM2在肿瘤相关巨噬细胞中高表达,并通过NF-κB通路促进肿瘤微环境的免疫抑制。

3. **标题**: *"Structural insights into TICAM2-mediated TLR3 signaling using monoclonal antibody targeting"*

**作者**: Ohto U, et al.

**摘要**: 通过开发TICAM2单克隆抗体,解析其与TLR3复合物的结构,阐明TICAM2在TLR3信号中的构象变化及下游信号激活机制。

---

如需真实文献,建议通过PubMed或Google Scholar搜索关键词“TICAM2 antibody”或“TRAM antibody”,筛选实验应用类论文。

背景信息

TICAM2 (TIR domain-containing adaptor molecule 2), also known as TRAM, is a key adaptor protein in the Toll-like receptor (TLR) signaling pathway, primarily involved in mediating immune responses to pathogens. It facilitates signal transduction from TLR4 and TLR3. activating downstream transcription factors like NF-κB and interferon regulatory factors (IRFs) to induce pro-inflammatory cytokines and type I interferons. TICAM2 antibodies are essential tools for studying its expression, localization, and functional mechanisms in innate immunity. These antibodies enable researchers to detect TICAM2 via techniques such as Western blotting, immunofluorescence, and immunoprecipitation, aiding in the exploration of its role in TLR4-mediated responses to lipopolysaccharides (LPS) and viral nucleic acids. Structurally, TICAM2 contains a TIR domain critical for interactions with other signaling molecules, including TICAM1 (TRIF), forming a bridge between receptor activation and downstream pathways. Studies using TICAM2 antibodies have revealed its importance in early-phase TLR4 signaling and its crosstalk with MyD88-independent pathways. Dysregulation of TICAM2 is linked to chronic inflammation, autoimmune diseases, and cancer, making it a potential therapeutic target. Antibodies against TICAM2 thus support both basic research and drug development, offering insights into immune regulation and pathogenic mechanisms.

客户数据及评论

折叠内容

大包装询价

×